| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8692091 | World Neurosurgery | 2018 | 8 Pages |
Abstract
Evidence documenting a causal association of natalizumab and PCNSL is weak. Considering the potential benefits of using natalizumab for current indications, we recommend vigilant monitoring of patients receiving the drug for PCNSL outlook.
Keywords
FDAPCNSLLPDHHVPMLLymphoproliferative disorderEBVimmunoglobulin Crohn diseasecraniotomyFood and Drug Administrationcentral nervous systemLymphomaPrimary central nervous system lymphomaProgressive multifocal leukoencephalopathyMultiple sclerosisNatalizumabEpstein-Barr virusHuman herpesvirushuman immunodeficiency virusHIV
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Menarvia Nixon, Richard P. Menger, Piyush Kalakoti, Jai Deep Thakur, Rimal H. Dossani, Kanika Sharma, Anil Nanda, Bharat Guthikonda,